The company looks to expand its lung leadership globally. Key product launches in US market will maximize value opportunities. Company performance is expected to improve with continued efforts on cost optimization and product improvisation. Hence, we reiterate our BUY rating on the stock with a TP of Rs. 1,050 based on 25x FY23E EPS. Sustained growth momentum in core therapies aids topline...